The Cohen lab studies mitochondrial microproteins. We take a systems biology approach to mitochondria, looking at mitochondrial ORFomics, mito-genomics, mitochondrial-epigenetics, mito-transcriptomics and mitochondrial-proteomics. Our discovery pipeline involves novel bioinformatic approaches to clone and advance disease-relevant mitochondrial-derived peptides. We utilize MiWAS (mitochondrial GWAS), MDPseq (mitochondrial RNAseq) and related tools, to identify new microproteins involved in diseases of aging. Over the last two decades we described multiple novel genes including humanin and its cytoprotective and neuroprotective roles; MOTS-c, which is an exercise-mimetic peptide in which a loss-of-function mutation predisposes to diabetes, that has been advanced to clinical trials in humans; SHLP2, which is involved in neurodegenerative diseases; SHMOOSE, a neuroprotective microprotein that harbors a mutation that predisposes to Alzheimer’s disease, and multiple other previously unrecognized microproteins. Our goal is to continue to develop diagnostic tools and therapeutic targets for health aging
The Cohen lab studies mitochondrial microproteins. We take a systems biology approach to mitochondria, looking at mitochondrial ORFomics, mito-genomics, mitochondrial-epigenetics, mito-transcriptomics and mitochondrial-proteomics. Our discovery pipeline involves novel bioinformatic approaches to clone and advance disease-relevant mitochondrial-derived peptides. We utilize MiWAS (mitochondrial GWAS), MDPseq (mitochondrial RNAseq) and related tools, to identify new microproteins involved in diseases of aging. Over the last two decades we described multiple novel genes including humanin and its cytoprotective and neuroprotective roles; MOTS-c, which is an exercise-mimetic peptide in which a loss-of-function mutation predisposes to diabetes, that has been advanced to clinical trials in humans; SHLP2, which is involved in neurodegenerative diseases; SHMOOSE, a neuroprotective microprotein that harbors a mutation that predisposes to Alzheimer’s disease, and multiple other previously unrecognized microproteins. Our goal is to continue to develop diagnostic tools and therapeutic targets for health aging
